KCNA4 encodes a voltage-gated potassium channel (Kv1.4) that mediates transmembrane potassium transport in excitable membranes. The channel forms tetrameric complexes—either homotetramers or heterotetramers with other Kv1 family members—that open in response to membrane depolarization and then rapidly inactivate, regulating action potential duration. KCNA4 is widely distributed in the central nervous system, retina, and cardiac tissue. Pathogenic variants in KCNA4 cause developmental epileptic encephalopathy; a de novo missense mutation (Kv1.4-V558L) in the channel selectivity filter resulted in severe loss-of-function properties and early-onset seizures 1. The gene also associates with congenital cataract, striatal abnormalities, and intellectual disability in a consanguineous family carrying a missense variant (p.Arg89Gln) that reduced channel current amplitude 2. In cardiac contexts, miR-448-mediated downregulation of KCNA4 in ischemia and heart failure diminishes the transient outward potassium current, contributing to arrhythmic risk 3. Additionally, KCNA4 variants show suggestive association with stimulant dependence in African-ancestry populations 4. Therapeutic inhibition of KCNA4 represents a mechanism of action for approved drugs including amifampridine and dalfampridine, which enhance acetylcholine availability at the neuromuscular junction to treat myasthenic syndromes 5.